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Background: Cardiac arrest due to torsades de pointes in patients with drug-induced long QT syndrome is a rare but catastrophic event. Few 
data exist regarding the prevalence of pre-existing QT interval prolongation in patients admitted to cardiac care units (CCUs) or the frequency of 
administering QT interval prolonging drugs to patients with pre-existing QT interval prolongation. Our objectives were to: 1) Determine the prevalence 
of Bazett’s-corrected QT (QTc) interval prolongation upon admission to CCU, and 2) Estimate the proportion of CCU patients with QT interval 
prolongation who are administered QT interval prolonging drugs during hospitalization.
Methods: Prospective, observational study in 900 consecutive patients admitted to the CCU in a large urban teaching hospital.
Results: Patient characteristics: age (mean ± SD) 65±16 years; 51.6% male; 62.4% Caucasian. Admitting diagnoses: heart failure (18.6%), 
myocardial infarction (13.6%), infection (11.1%), atrial fibrillation (7.0%), ventricular tachycardia (3.1%), and cardiac arrest (1.4%). QTc interval 
prolongation was present in 50% of patients on admission (Table). QT interval prolonging drugs were commonly prescribed for patients with pre-
existing QTc interval prolongation (Table).
Conclusions: QT interval prolonging drugs are commonly prescribed to CCU patients with pre-existing QT interval prolongation. Strategies should 
be developed to avoid administration of QT prolonging drugs in vulnerable patients. 
Males Females All patients 
QTc interval on admission (ms) 452 ± 55 465 ± 48 462 ± 47
Admitting QTc >450 [males] or > 470 ms [females] 
(95% CI)
56.2%
(51.7%-60.7%)
n=261/464
42.4%
(37.9%-46.9%)
n=185/436
49.6%
(46.3%-52.9%)
n=446/900
Admitting QTc > 500 ms (95% CI)
18.9%
(15.3%-22.5%)
n=88/464
17.8%
(14.3%-21.3%)
n=78/436
18.4%
(15.9%-20.9%)
n=166/900
Patients with admitting QTc >450 [males] or > 470 
[females] administered QT-prolonging drugs during 
CCU stay (95% CI)
22.2%
(17.1%-27.3%)
n=58/261
17.8%
(12.3%-23.3%)
n=33/185
20.4%
(16.7%-24.1%)
n=91/446
Patients with admitting QTc > 500 ms administered 
QT-prolonging drugs during CCU stay (95% CI)
45.4%
(34.8%-56.0%)
n=40/88
38.5%
(28.0%-49.0%)
n=30/78
42.4%
(34.9%-49.9%)
n=70/166
